
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Dualyx NV raises €40m in Series A financing
The Series A financing was co-led by Fountain Healthcare Partners, Forbion and Andera Partners and seed investors V-Bio Ventures, BGV, PMV, VIB,...

Noema Pharma AG closes Series B financing
CNS specialist Noema Pharma has cashed in €104m in an oversubscribed Series B fianancing co-led by Jeito Capital and Forbion. New investors such as...

eXmoor Pharma Ltd raises US$35m
The financing of eXmoor Pharma Ltd. was led by new investor Kineticos Ventures and existing investor MVM Partners to help launching...

High blood pressure reprograms immune system
German scientists headed by Suphansa Sawamiphak from MDC Berlin have discovered in a zebrafish and mouse model of salt-induced hypertension that...

LanzaTech and Plastipak produce greener PET
The PPKNatura resin might safe up to 30% carbon emissions because it replaces petroleum-based monoethylene glycol (MEG), together with terephtalic...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...